Abstract
Taxol is the most exciting new anticancer agent developed in the past two decades. Of great interest is its level of activity in ovarian cancer, as well as substantial activity in breast cancer, nonsmall-cell lung cancer, melanoma, and other malignancies. Recent studies suggest that when taxol is administered in a fashion to increase milligram dosage per unit time (mg/m2/week), the response rate in patients with ovarian cancer is markedly increased. This article reviews studies that suggest taxol dose intensity is important in the treatment of patients with ovarian cancer.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Donehower R. C., Rowinsky E. K., Grochow L. B., Longnecker S. M., Ettinger D. S. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep. 1987 Dec;71(12):1171–1177. [PubMed] [Google Scholar]
- Einzig A. I., Gorowski E., Sasloff J., Wiernik P. H. Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest. 1991;9(2):133–136. doi: 10.3109/07357909109044223. [DOI] [PubMed] [Google Scholar]
- Holmes F. A., Walters R. S., Theriault R. L., Forman A. D., Newton L. K., Raber M. N., Buzdar A. U., Frye D. K., Hortobagyi G. N. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991 Dec 18;83(24):1797–1805. doi: 10.1093/jnci/83.24.1797-a. [DOI] [PubMed] [Google Scholar]
- Lipton R. B., Apfel S. C., Dutcher J. P., Rosenberg R., Kaplan J., Berger A., Einzig A. I., Wiernik P., Schaumburg H. H. Taxol produces a predominantly sensory neuropathy. Neurology. 1989 Mar;39(3):368–373. doi: 10.1212/wnl.39.3.368. [DOI] [PubMed] [Google Scholar]
- McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F. C., Ettinger D. S., Armstrong D. K., Donehower R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273–279. doi: 10.7326/0003-4819-111-4-273. [DOI] [PubMed] [Google Scholar]
- Rowinsky E. K., Burke P. J., Karp J. E., Tucker R. W., Ettinger D. S., Donehower R. C. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res. 1989 Aug 15;49(16):4640–4647. [PubMed] [Google Scholar]
- Rowinsky E. K., Cazenave L. A., Donehower R. C. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990 Aug 1;82(15):1247–1259. doi: 10.1093/jnci/82.15.1247. [DOI] [PubMed] [Google Scholar]
- Rowinsky E. K., McGuire W. P., Guarnieri T., Fisherman J. S., Christian M. C., Donehower R. C. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991 Sep;9(9):1704–1712. doi: 10.1200/JCO.1991.9.9.1704. [DOI] [PubMed] [Google Scholar]
- Simone J. V., Meyer W. H., Link M. P. Osteosarcoma: good news despite crude tools. J Clin Oncol. 1992 Jan;10(1):1–2. doi: 10.1200/JCO.1992.10.1.1. [DOI] [PubMed] [Google Scholar]
- Wiernik P. H., Schwartz E. L., Einzig A., Strauman J. J., Lipton R. B., Dutcher J. P. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol. 1987 Aug;5(8):1232–1239. doi: 10.1200/JCO.1987.5.8.1232. [DOI] [PubMed] [Google Scholar]
- Wiernik P. H., Schwartz E. L., Strauman J. J., Dutcher J. P., Lipton R. B., Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 1987 May 1;47(9):2486–2493. [PubMed] [Google Scholar]